---
layout: default
title: Cinchocaine
parent: 僅模型預測 (L5)
nav_order: 139
evidence_level: L5
indication_count: 7
---

# Cinchocaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cinchocaine: From Local Anesthesia to Bronchitis

## One-Sentence Summary

Cinchocaine (dibucaine) is a potent amide-type local anesthetic globally recognized for topical pain relief in conditions such as hemorrhoids and minor skin procedures, though it holds no registered approvals in Saudi Arabia.
The TxGNN model predicts it may be effective for **bronchitis**, based on indirect class-level mechanistic reasoning linking sodium channel blockade to airway anti-inflammation.
Currently, there are **no clinical trials** and **no publications** directly supporting this repurposing direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Local anesthesia (hemorrhoids, skin/mucous membrane pain) — no Saudi Arabia authorization on record |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacological knowledge, Cinchocaine (dibucaine) is one of the most potent and longest-acting amide-type local anesthetics. Its primary mechanism involves blockade of voltage-gated sodium channels (Nav), which prevents membrane depolarization and nerve impulse conduction. It has historically been applied topically for hemorrhoid-associated pain, pruritus ani, and minor mucosal/skin procedures.

The TxGNN model's prediction for bronchitis appears to draw on a broader class-level observation: amide-type local anesthetics — particularly lidocaine — have shown systemic anti-inflammatory properties in airway inflammation models. Proposed mechanisms include inhibition of neutrophil chemotaxis, suppression of pro-inflammatory cytokines (notably IL-6 and TNF-α), and downregulation of TLR-mediated signaling cascades. These properties have generated academic interest in intravenous lidocaine as an adjunct in COPD exacerbations and asthmatic bronchitis.

However, this prediction must be interpreted with caution. The mechanistic link relies entirely on class-level extrapolation from lidocaine research; there is no direct preclinical or clinical evidence demonstrating that Cinchocaine specifically suppresses airway inflammation. The TxGNN model may be reflecting a topological proximity in the knowledge graph between "amide local anesthetic" nodes and "airway inflammatory disease" nodes, rather than a Cinchocaine-specific biological signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Cinchocaine currently holds no product authorizations in Saudi Arabia. The drug is not marketed in the Saudi market, and no approved dosage forms or indications are on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top predicted indication (bronchitis) and all six additional predictions carry L5 evidence — model output only, with zero supporting clinical trials or publications. The drug is not registered in Saudi Arabia, and both the mechanism of action and safety profile remain formally undocumented in the Evidence Pack.

**To proceed, the following is needed:**

- **MOA documentation**: Retrieve full mechanism of action from DrugBank API (DG002) to enable formal mechanistic plausibility analysis
- **Safety profile**: Download and parse the package insert (DG001) to populate warnings, contraindications, and DDI data before any S1 safety evaluation
- **Preclinical evidence search**: Conduct a targeted PubMed search for Cinchocaine (dibucaine) + inflammation / cytokine / airway to determine whether class-level effects apply specifically to this compound
- **Comparator benchmark**: Assess whether lidocaine — with a stronger existing evidence base for airway anti-inflammation — is a more appropriate repurposing candidate in this disease area
- **Regulatory pathway assessment**: If evidence is strengthened, map a Saudi Arabia (SFDA) regulatory pathway for a non-marketed compound before committing development resources
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

